Biocon Joins Pending Validity Review of Regeneron Eylea Patent

Biocon Biologics Inc. can act as a “silent understudy” to fellow biosimilars maker Samsung Bioepis Co. in a pending validity review of a Regeneron Pharmaceuticals Inc. patent for Eylea, an administrative tribunal said.

The petition by Biocon, a unit of Biocon Ltd., “advances essentially identical arguments, challenging the same claims over the same combinations of prior art” as the Samsung Biologics Co. unit’s earlier request to launch an inter partes review, which the Patent Trial and Appeal Board granted in November 2021, according to an order the PTAB issued Tuesday.

“We consequently adopt the same reasoning” as in the ...